ABSTRACT
The integration of vertical control programmes of neglected tropical diseases (NTDs) aims to contain operational cost, simplify the application of the control measures and further extend the coverage of interventions. The Preventive Chemotherapy and Transmission Control (PCT) databank was established by the WHO to facilitate access and sharing of information from national programmes with stakeholders involved in NTD control. The PCT databank contains compilations of historical and current information on disease-specific epidemiological situations, the geographical overlapping of NTDs and progress of control activities in all the NTD-endemic countries. A summary of country-specific epidemiological maps and the progress of control activities are available from the online PCT databank and the Country Profiles. Annual progress of preventive chemotherapy interventions targeting specific NTDs is reported in the Weekly Epidemiological Record (WER) published annually for each disease targeted. In this paper, the method of data collection and compilation used to establish the PCT databank is explained and the key features of the online PCT databank, the Country Profiles and WER are presented.
Subject(s)
Antiparasitic Agents/administration & dosage , Chemoprevention/methods , Communicable Disease Control , Communicable Diseases/drug therapy , Databases as Topic , Infectious Disease Transmission, Vertical/prevention & control , Neglected Diseases/prevention & control , Communicable Disease Control/methods , Communicable Disease Control/organization & administration , Communicable Disease Control/trends , Communicable Diseases/epidemiology , Cost-Benefit Analysis , Female , Humans , Infectious Disease Transmission, Vertical/statistics & numerical data , Male , Neglected Diseases/drug therapy , Neglected Diseases/epidemiology , Pregnancy , Public Health , World Health OrganizationABSTRACT
PURPOSE: To evaluate the frequency and epidemiological features of vernal keratoconjunctivitis (VKC) in Italy. METHODS: a specific electronic clinical chart for vernal keratoconjunctivitis was created to standardize: 1) medical history; 2) diagnostic criteria; 3) signs and symptoms; and 4) treatments. This study involved 6 Italian referral centers for ocular surface diseases: between March 2005 and March 2006, all referred patients were included, clinical data collected and statistically examined. RESULTS: The mean age of the vernal keratoconjunctivitis population (n = 156) was 13.8 +/- 8.8 with 64.1% of subjects under 14 years of age and a male/female ratio of 3.5:1. Among VKC patients, 48.7% showed associated systemic allergic diseases. Only 32.1% of patients were positive for RAST and/or prick test. The limbal form (53.8%) was the most frequent subtype of vernal keratoconjunctivitis. Approximately 9% of patients showed a severe form of vernal keratoconjunctivitis. At the first visit patients were treated with: multiple action or mast cell stabilizer eye drops (58.1% and 41.3% of cases, respectively), topical corticosteroids alone (0.6%) or in association (26.8% of cases). All patients used topical steroids at least once in the studied year. Systemic antihistamine therapy was used by 25.6% of patients. In this cohort, 32.7% of patients required two or more examinations per year for exacerbations of their symptoms. CONCLUSION: Vernal keratoconjunctivitis is a severe ocular condition that mainly affects young males. Vernal keratoconjunctivitis is characterized by different clinical features and therapeutic responses, suggesting the need for a standardized therapeutic approach on the basis of a grading of disease severity.
Subject(s)
Conjunctivitis, Allergic/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Child , Child, Preschool , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/drug therapy , Female , Glucocorticoids/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Italy/epidemiology , Male , Middle Aged , Prospective Studies , Sex DistributionABSTRACT
PURPOSE: Glial cells and fibroblasts (FBs) play a key role in epiretinal membrane (ERM) development and progression. Myofibroblasts (myoFBs), arising from these cells, can lead to the hypertrophic scars and tissue contraction observed in ERMs. Nerve growth factor (NGF) and transforming growth factor-beta1 (TGF-beta1) play a crucial role in FB activities. Therefore, the authors evaluated myoFBs in ERMs and NGF, trkA(NGFR and p75(NTR) expression, as well as TGF-beta1/TGF-betaRII levels in both ERMs and vitreous. METHODS: Eight idiopathic ERMs and vitreous were obtained from patients at the time of vitrectomy for macular pucker. Ten control vitreous were from donors. Biochemical and molecular analyses were performed to identify alpha-smooth muscle actin (alpha-SMA, a defined myoFB marker), NGF, trkA(NGFR)/p75(NTR), and TGF-beta1/TGF-betaRII. RESULTS: Every idiopathic ERM displayed alpha-SMA positive myoFBs, expressing NGF, trkA(NGFR), and p75(NTR). ERM vitreous showed a significant decrease in NGF protein coupled with a TGF-beta1 increase. In addition, vitreous cells showed an increase in trkA(NGFR)/p75(NTR) mRNA associated with a decrease in TGF-betaRII mRNA. CONCLUSIONS: Idiopathic ERMs were characterized by myoFBs. The expression of NGF, trkA, and p75 in local myoFBs associated with changes in ERM vitreous NGF suggests an involvement of NGF, as previously reported for TGF-beta1, in the evolution and myoFB-mediated contractile activity of ERMs.
